BB&T Corp reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 282,030 shares of the biopharmaceutical company’s stock after selling 4,099 shares during the period. BB&T Corp’s holdings in Gilead Sciences were worth $19,962,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the last quarter. West Oak Capital LLC boosted its position in Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares in the last quarter. Westover Capital Advisors LLC boosted its position in Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares in the last quarter. Abner Herrman & Brock LLC boosted its position in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares in the last quarter. Finally, ARS Investment Partners LLC boosted its position in Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares in the last quarter. Institutional investors own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 1.766% during midday trading on Thursday, reaching $72.595. The company had a trading volume of 4,069,783 shares. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.10. The company has a 50-day moving average price of $72.16 and a 200 day moving average price of $68.73. The company has a market capitalization of $94.80 billion, a P/E ratio of 7.885 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.08 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Stake Decreased by BB&T Corp” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-stake-decreased-by-bbt-corp/1471344.html.

A number of research analysts have issued reports on the company. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a research report on Friday, July 28th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Twelve research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $80.31.

In related news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock valued at $15,223,184 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.